Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Stabilized enzymes or enzymes complexed with nonenzyme
Reexamination Certificate
2006-05-09
2006-05-09
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Stabilized enzymes or enzymes complexed with nonenzyme
C435S188000, C436S519000, C514S002600
Reexamination Certificate
active
07041287
ABSTRACT:
Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots, which are capable of selective dissolution of pathological nascent clots formed intravascularly, with minimal risk of unwanted dissolution of pre-existing hemostatic clots, are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.
REFERENCES:
Kajihara et al., “Physiochemical characterization of PEG-PPG conjugated human urokinase”, Biochimica et Biophysica Acta 1994 1199:202-208.
Muzykantov et al., “Regulation of the Complement-Mediated Elimination of Red Blood Cells Modified with Biotin and Streptavidin”, Analytical Biochemistry 1996 241:109-119.
Bdeir et al., “Urokinase mediates fibrinolysis in the pulmonary microvasculature”, Blood 2000 96(5) :1820-1826.
Collen D., “Towards improved thrombolytic therapy”, Lancet 1993 342:34-36.
Collen et al., “Mechanisms of activiation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase”, Eur. J. Biochem. 1993 216:307-314.
Fears R. and G. Poste, “Obstacles to the Development of Novel Thrombolytic Agents for Acute Myocardial Infarction Therapy : Is the Good the Enemy of the Best?”, Fibrinolysis 1994 8:203-213.
Heeremans et al., “Thrombolytic Treatment with Tissue-type Plasminogen Activator (t-PA) Containing Liposomes in Rabbits:a Comparison with Free 5-PA”, Throm. Haemost. 1995 73:488-494.
Holvoet et al., “Thrombolytic Profiles of Clot-Targeted Plasminogen Activators—Parameters Determining Potency and Initial Maximal Rates”, Circulation 1993 87:1007-1016.
Kalofonos et al., “Imaging of Tumor in Patients with Indium-111-Labeled Biotin and Streptavidin-Conjugated Antibodies:Preliminary Communication”, J. Nucl. Med. 1990 31:1791-1796.
Kinoshita K. and T. Tsong, “Survival of sucrose-loaded erythrocytes in the circulation”, Nature 1978 272:258-260.
Krishnamurti et al., “PAI-1-Resistant t-PA:Low Doses Prevent Fibrin Deposition in Rabbits With Increased PAI-Activity”, Blood 1996 87:14-19.
Lijnen R. and D. Collen, “Remaining Perspectives of Mutant and Chimeric Plasminogen Activators”, Ann. NY Acad. Sci. 1992 667:357-364.
Murciano et al., “Platelets inhibit the lysis of pulmonary microemboli”, Am. J. Physiol. Lung Cell Mol. Physiol, 2002 282:L529-L539.
Muzykantov et al., “Targeting of enzyme immobilized on erythrocyte membrane to collagen-coated surface”, FEBS Lett. 1985 182:62-66.
Muzykantov et al., “Directed Targeting of Immunoerythrocytes Provides Local Protection of Endothelial Cells From Damage by Hydrogen Peroxide”, Am. J. Pathol. 1987 128:276-285.
Muzykantov et al., “Avidin-induced lysis of biotinylated erythrocytes by homologous complement via the alternative pathway depends on avidin's ability of multipoint binding with biotinylated membrane”, Biochim. Biophys. Acta 1992 1107:119-125.
Muzykantov et al., “Fast lysis by complement and uptake by liver of avidin-carrying biotinylated erythrocytes”, Int. J. Artif. Organs 1992 15 (10) :622-627.
Muzykantov et al., “Avidin acylation prevents the complement-dependent lysis of avidin-carrying erythrocytes”, Biochem. J. 1991 273:393-397.
Muzykantov et al., “Tannin-Mediated Attachment of Avidin Provides Complement-Resistant Immunoerythrocytes That Can Be Lysed in the Presence of Activator of Complement”, Anal Biochem. 1993 208:338-342.
Muzykantov et al., “Immunotargeting of erythrocyte-bound streptokinase provides local lysis of a fibrin clot”, Biochimica et Biophysica Acta 1986 884:335-362.
Muzykantov et al., “Immunotargeting of antioxidant enzymes to the pulmonary endothelium”, Proc. Natl. Acad. Sci. USA 1996 93:5213-5218.
Narita et al., “Two Receptor Systems Are Involved in the Plasma Clearance of Tissue-type Plasminogen Activator (t-PA) In Vivo”, J. Clin. Invest. 1995 96:1164-1168.
Pardridge et al., “Vector-mediated delivery of a polyamide (“peptide”) nucleic acid analogue through the blood-brain barrierin vivo”, Proc. Natl. Acad. Sci. USA 1995 92:5592-5596.
Plow et al., “The cell biology of the plasminogen system”, FASEB J. 1995 9:939-945.
Poznansky M. and R. Juliano, “Biological Approaches to the Controlled Delivery of Drugs:A Critical Review”, Pharmacol. Rev. 1984 36:277-324.
Reilly et al., “Both Circulating and Clot-Bound Plasminogen Activator Inhibitor-1 Inhibit Endogenous Fibrinolysis in the Rat”, Arterioscl. Thromb. 1991 11:1276-1286.
Sakharov D. and D. Rijken, “Superficial Accumulation of Plasminogen During Plasma Clot Lysis”, Circulation 1995 92:1883-1890.
Samokhin et al., “Red blood cell targeting to collagen-coated surfaces”, FEBS 1983 154 (2) :257-261.
Schnaper et al., “Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways”, J. Cellular Physiology 1995 165:107-118.
Wilchek M. and E. Bayer, “The Avidin-Biotin Complex in Bioanalytical Applications”, Anal. Biochem. 1988 171:1-32.
Cines Douglas
Murciano Juan Carlos
Muzykantov Vladimir R.
Borin Michael
Licata & Tyrrell P.C.
Trustees of the University of Pennsylvania
LandOfFree
Compositions and methods for selective dissolution of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for selective dissolution of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for selective dissolution of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3632672